🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP

RecruitingPhase 4Ages 18 Years - 65 YearsAllUniversity of Virginia
NCT05094570 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Hypothesis: The investigators hypothesize that in patients with CRSwNP who demonstrate sinus colonization with staphylococcus aureus, the administration of dupilumab will be associated with decreased staph colonization and an increase in microbial diversity. Primary Objective will be to demonstrate that dupilumab reduces staphylococcus aureus (phyla firmicutes) abundance while increasing microbial diversity in patients with CRSwNPs who are culture positive for staph aureus at enrollment. Secondary Objectives will be to correlate reduction in Staph aureus abundance and improved bacterial diversity with increased expression of anti-microbial proteins (ß-defensins1-4) and cathelicidin LL-37. In addition, the investigators will correlate improvements in microbial diversity/decreased staph abundance with clinical improvements as assessed via questionnaires and objective/subjective smell fun

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: • Adults, ages 18-65 * History of CRSwNP including subjects with AERD * Sinonasal culture demonstrating staph aureus at visit 1 * History of FESS with patent sinus ostia sufficient to obtain culture and tissue samples from the middle meatus * Asthma, if present, should be well controlled * Atopic dermatitis, if present, should be well controlled * Use of nasal saline irrigation and stable dosing (\>1 month) of topical corticosteroids is permitted * Intent of the physicians caring to start dupilumab therapy as part of subject's standard of care * Subject meets FDA approved criteria for the use of dupilumab for nasal polyps Exclusion Criteria: * Concurrent serious medical problem * Uncontrolled asthma (ACT \<20 at screening visit) * Recent (within 60 days) use of oral corticosteroids * Recent (within 60 days) urgent care, ED visit, or hospitalization for asthma * Current smoker or has smoked \>10 pack-years * Biologic therapy including asthma biologic therapy in last 3 months * Recent (within 1 month) change in CRS medical treatment (topical steroids, surfactants, irrigation protocol, etc. including changes in delivery volume or delivery methodology) * Recent (within 6 weeks) upper respiratory infection * Antibiotics within 6 weeks * Pregnant or breast-feeding women * Any contraindication to the use of dupilumab including hypersensitivity on previous administration
💊

What it tests

  • Dupilumab Prefilled Syringe
📍

Where

1 site
University of Virginia Health System
Charlottesville, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy